An integrated analysis identifies six molecular subtypes of pancreatic ductal adenocarcinoma revealing cellular and molecular landscape

• Published in: Carcinogenesis (New York) Vol. 44; no. 10-11; pp. 726 - 740
• Main Authors: Li, Lixing, Shen, Lu, Wu, Hao, Li, Mo, Chen, Luan, Zhou, Qiang, Ma, Jingsong, Huai, Cong, Zhou, Wei, Wei, Muyun, Zhao, Mingzhe, Zhao, Xianglong, Du, Huihui, Jiang, Bixuan, Sun, Yidan, Zhang, Na, Qin, Shengying, Xing, Tonghai
• Format: Journal Article
• Language: English
• Published: UK Oxford University Press 15.12.2023
• ISSN: 0143-3334; 1460-2180
• DOI: 10.1093/carcin/bgad068

Abstract Pancreatic ductal adenocarcinoma (PDA) has been found to have a high mortality rate. Despite continuous efforts, current histopathological classification is insufficient to guide individualized therapies of PDA. We first define the molecular subtypes of PDA (MSOP) based on a meta-cohort of 845 samples from 11 PDA datasets. We then performed functional analyses involving immunity, fibrosis and metabolism. We recognized six molecular subtypes with different survival statistics and molecular composition. The squamous basal-like (SBL) subtype had a poor prognosis and high infiltration of ENO1+ (Enolase 1)/ADM+ (Adrenomedullin) cancer-associated fibroblasts (CAFs). The immune mesenchymal-like (IML) subtype and the normal mesenchymal-like (NML) subtype were characterized by genes associated with extracellular matrix (ECM) activities and immune responses, having favorable prognoses. IML was featured by elevated exhausted immune signaling and inflammatory CAFs infiltration, whereas NML was featured with myofibroblastic CAFs infiltration. The exocrine-like (EL) subtype was high in exocrine signals, while the pure classical-like (PCL) subtype lacked immunocytes infiltration. The quiescent-like (QL) subtype had diminished metabolic signaling and high infiltration of NK cells. SBL, IML and NML were enriched in innate anti-PD-1 resistance signatures. In sum, this MSOP depicts a vivid cell-to-molecular atlas of the tumor microenvironment of PDA and might facilitate to design a precise combination of therapies that target immunity, metabolism and stroma. Pancreatic cancer could be stratified into six molecular subtypes of pancreatic cancer, including squamous basal-like subtype, immune mesenchymal-like subtype, normal mesenchymal-like subtype, exocrine-like subtype, pure classical-like subtype and quiescent-like subtype. Graphical Abstract Graphical Abstract